RAYALDEE

This brand name is authorized in Ireland, United States

Active ingredients

The drug RAYALDEE contains one active pharmaceutical ingredient (API):

1 Calcidiol UNII P6YZ13C99Q - CALCIFEDIOL

Vitamin D3 must undergo a two-step metabolic process to be active; the first step occurs in the microsomal fraction of the liver where Vitamin D is hydroxylated at position 25 (25-hydroxycholecalciferol or calcifediol); the second step takes place in the kidney where 1,25-dihydroxycholecalciferol or calcitriol is formed due to the activity of enzyme 25-hydroxycholecalciferol 1-hydroxylase. Vitamin D increases absorption of calcium and phosphorus in the intestine and improves normal bone formation and mineralization. Read about Calcidiol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RAYALDEE Extended-release capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H05BX05		H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05B Anti-parathyroid agents → H05BX Other anti-parathyroid agents
Discover more medicines within H05BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 70301-1001